M
$145.9–234.2K / year · Cambridge, Massachusetts, US
Moderna develops and commercialises mRNA-based medicines and vaccines, with approved products for COVID-19 and RSV and 45 development programmes across infectious disease, oncology and other areas.
Moderna is a biotechnology company that develops and commercialises medicines and vaccines based on messenger RNA (mRNA). Founded in 2010 and headquartered in Cambridge, Massachusetts, the company has built its mRNA technology platform over more than a decade, with 18 locations worldwide. Its platform allows for the design, research and testing of multiple mRNA sequences within days, supporting rapid iteration across development programmes.
The company's approved products include SPIKEVAX and mNEXSPIKE, both COVID-19 vaccines, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Beyond these, Moderna reports 45 development programmes and 36 ongoing clinical trials spanning infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases.
Moderna describes its approach as fighting illness differently from traditional medicine, applying mRNA to a range of therapeutic and preventive areas beyond vaccines. The company has stated commitments on sustainability, including net-zero carbon emissions for Scopes 1 and 2 by 2030 and for Scope 3 by 2045.